Key Highlights
- Shares are trading at $12.22 in pre-market activity, up 3.21% from Thursday's close of $11.84.
- Management's presentation at the H.C. Wainwright 28th Annual Global Investment Conference outlined an expanded total addressable market for MIPLYFFA, now estimated at 350-900 patients versus the original 350 estimate at approval.
- The company disclosed 184 registration enrollment forms filed since launch, with U.S. commercial uptake running stronger than expected and about 50% of enrolled patients being adults, a previously underdiagnosed group.
- The pre-market strength also comes amid a broader healthcare sector rebound following the Federal Reserve's rate decision.
Conference Presentation Highlights an Expanded Market Opportunity
Zevra Therapeutics (NASDAQ:ZVRA) shares gained in pre-market trading Friday, building on investor enthusiasm following management's presentation at the H.C. Wainwright 28th Annual Global Investment Conference this week. Zevra Therapeutics, founded in 2006 as KemPharm and rebranded in February 2023, is a Boston-headquartered commercial-stage biopharmaceutical company dedicated to developing and delivering therapies for people living with rare diseases.
Chief Executive Officer Neil McFarlane outlined a sharply expanded total addressable market for MIPLYFFA (arimoclomol), approved in 2024 for Niemann-Pick disease type C, now estimated at 350 to 900 patients compared with the original 350-patient estimate at the time of approval.
Stronger-Than-Expected Commercial Uptake Reinforces the Story
The company disclosed 184 registration enrollment forms filed since launch, with U.S. commercial uptake running stronger than expected. Notably, about 50% of enrolled patients are adults, a group the company says was previously underdiagnosed, suggesting the addressable patient population may be broader than initially modeled.
Pipeline Progress and Sector Tailwinds Add Support
Zevra continues to navigate European regulatory review after an initial negative CHMP opinion and is advancing its celiprolol trial for vascular Ehlers-Danlos syndrome. The stock's pre-market strength also comes amid a broader healthcare sector rebound following the Federal Reserve's rate decision, as investors weigh Zevra's transformation into a commercial-stage rare disease company against execution risks tied to European expansion timing and Capital deployment.






Please wait processing your request...